Contribute Try STAT+ Today

The price of a Gilead Sciences (GILD) pill approved in the U.S. last fall to prevent HIV would have to be cut nearly in half in order to be cost-effective because it has questionable benefits over an older, similar pill that will face lower-cost generic competition later this year, according to a new analysis.

As a result, the authors argued that switching to the newer medicine might limit access and boost HIV transmission. For its part, the drug maker shot back the methodology used in the study was “flawed” and led to “inaccurate conclusions that severely underestimate the value” of the newer medicine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It seems Gilead clearly did not approach Rochelle P. Walensky and ask whether she would be willing to serve a consultant for the company and if so, for how much!

Comments are closed.